Attorney General trying to intimidate witness testifying about live fetal hearts: lawyers – Lifesite

SAN FRANCISCO, California, September 17, 2019 (LifeSiteNews) Lawyers for pro-life journalists David Daleiden and Sandra Merritt are accusing Californias deputy attorney general of trying to intimidate and threaten a critical expert witness.

Dr. Theresa Deisher, an expert in stem cell research at Stanford University, is set to testify for the defense Wednesday.

But Deputy Attorney General Johnette Jauron asked Daleiden on cross-examination Monday if Deisher was party to the undercover operation that led to his and Sandra Merritts criminal prosecution.

Daleiden and Merritt of the Center for Medical Progress (CMP) are charged with 14 felony counts of illegal recording in connection with undercover videos CMP released in 2015 that exposed Planned Parenthoods trafficking in aborted baby body parts. Originally they were charged with 15 felony counts, but one of those charges was dropped Friday.

Daleiden testified that he consulted Deisher only about the science of stem cell research, and that she was not privy to his covert investigation.

In earlier testimony, Daleiden said he asked Deisher and other experts whether a 2102 Stanford study in which aborted baby hearts supplied by StemExpress that were perfused in a Langendorff apparatus would require that the hearts be beating.

Dr. Deisher told me the fetus would have to be alive at the time the organs were harvested for use in the Langendorff apparatus, he told the court.

In light of Jaurons questions, Judge Christopher C. Hite told defense counsel Tuesday that Deisher might need to consult a lawyer regarding her testimony, since the attorney general had raised the possibility of a prosecution against her.

Defense lawyers swiftly rejected the idea.

Its absurd, and a waste of time, Daleidens lawyer Brentford Ferreira told the court.

I believe this is being done to intimidate the witness.

Horatio Mihet of Liberty Counsel, a lawyer for Merritt, also blasted the ridiculousness of the suggestion Deisher needed a lawyer.

Hite, however, told them that he couldnt ignore that they may or may not prosecute and that it was within his discretion as a judge to counsel Deisher to seek legal advice.

When Deisher was sworn in as a witness just before the court adjourned on Tuesday, the judge told her he had information that would compel me to advise you you have the right to seek an attorney.

It is not clear at this time if Deisher has done so.

Nicolai Cocis, a California attorney who is representing Merritt, excoriated the move.

Essentially the attorney general is threatening a critical witness with prosecution if she testifies, he told LifeSiteNews.

They think that David and she conspired, Cocis said. But they havent talked to her directly.

If I, as a defense lawyer, threatened a prosecution witness the way they are threatening our defense witness, I would be facing criminal charges, he added.

Jauron asked Daleiden on cross-examination Tuesday about Deisher being listed as one of his project consultants in his January 2013 proposal for an in-depth undercover investigation into the illegal trafficking in aborted baby body parts.

Deisher was listed in my project for donors as one of my experts in stem cell research, Daleiden said.

She, in fact, consulted with you in anticipation of your investigation, Jauron said.

Daleiden replied that during the time he was preparing himself and his investigative team for the undercover operation, he asked Deisher scientific questions to be thoroughly conversant with the stem cell research and fetal tissue procurement field.

He testified that he met Deisher in 2010, and talked to her on the phone about four times a year from 2010 to 2014. He had a couple more detailed discussions with her about some of the conversations he and Merritt recorded in 2014 before the videos were released.

He believed Deisher was provided with some videos through defense counsel for her role as an expert witness in the case, Daleiden told the court.

Jauron asked Daleiden if he paid Deisher, and he said no.

Deisher is expected to testify Wednesday morning.

Read this article:
Attorney General trying to intimidate witness testifying about live fetal hearts: lawyers - Lifesite

Demand for Stem Cell-Derived Cells Market Driven by Shifting Consumer Perceptions and Growing Awareness – My Health Reporter

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors. These stem cell-derived cells are then developed using a complete culture system that is an easy-to-use system used for defined iPS-derived cell expansion. Majority of the key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/28780

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

If you have any query, ask the analyst @ https://www.persistencemarketresearch.com/ask-an-expert/28780

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Need Customization on this Report? Ask here @ https://www.persistencemarketresearch.com/request-customization/28780

Report Highlights:

See the original post:
Demand for Stem Cell-Derived Cells Market Driven by Shifting Consumer Perceptions and Growing Awareness - My Health Reporter

Major Players of Serum-Free Media Market By Type: protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media -…

This report rigorously investigates the potential of the Serum-Free Media Market in conjunction with primary market challenges.

The report on Serum-Free Media is a professional report which provides thorough knowledge along with complete information pertaining to the Serum-Free Media industry which propose classification, applications, industry chain summary and policies in addition to plans, product specifications, manufacturing processes, and cost structures, among others.

The present market condition and future prospects of the segment has also been examined.

Moreover, key strategies in the market that includes product developments, partnerships, mergers and acquisitions, etc., are discussed.

Besides, upstream raw materials and equipment and downstream demand analysis is also conducted.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/137537

The report presents the market analysis and projection of Serum-Free Media on a regional as well as global level. The report constitutes qualitative and quantitative valuation by industry analysts, first-hand data, assistance from industry experts along with their most recent verbatim and each industry manufacturers via the market value chain.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, coveringThermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Lonza, Corning Incorporated, Irvine Scientific, STEMCELL Technologies Inc., PAN Biotech, MP Biomedicals, LLC, PromoCell GmbH

By Typeprotein expression media, stem cell media, hybridoma media, primary cell media, insect cell media, immunology media, Chinese hamster cell (CHO) culture media, chemically defined media,

By End userbiopharmaceutical companies, clinical research organizations, academic research centers

The fact that this market report renders details about the major market players along with their product development and current trends proves to be very beneficial for fresh entrants to comprehend and recognize the industry in an improved manner. The report also enlightens the productions, sales, supply, market condition, demand, growth, and forecast of the Serum-Free Media industry in the global markets.

Grab amazing discount here @ https://www.alexareports.com/check-discount/137537

Every regions market has been studied thoroughly in this report which deals with the precise information pertaining to the Marketing Channels and novel project investments so that the new entrants as well as the established market players conduct intricate research of trends and analysis in these regional markets. Acknowledging the status of the environment and products up gradation, the market report foretells each and every detail.

Review of the chapters evaluating the global Serum-Free Media market in detail:

Chapter 1 provides an in-depth analysis of the Serum-Free Media introduction, covering the scope of the product, review growth potentials, risks associated with the product, driving forces of the market, etc.

Chapter 2 enlists the leading providers of the Serum-Free Media Market by sales, revenue etc. throughout the forecast period.

Chapter 3 provides the competitive scenario of the leading pioneers on the basis of sales, revenue, market share etc. over the coming years.

Chapter 4 segments the global market by geography and their market share, sales, revenue etc. for the period 2019 to 2024.

Chapters 5 to 9 assesses the regions with Serum-Free Media countries based on market share, revenue, sales etc.

Chapter 10 and 11 provides a brief of the market segments such as the types, applications, sales, market share, growth rate etc. for forecast period.

Chapter 12 focuses on the market forecast for the entire time frame for the Serum-Free Media Market by regions, type and application, sales, and revenue.

Chapter 13 to 15 provides subtle details regarding the sales channels, distributors, traders, dealers, as well as research findings, research findings, and conclusion etc. for the Serum-Free Media Market.

To Enquire About This Comprehensive Report, Click Here: https://www.alexareports.com/send-an-enquiry/137537

In the end, the report covers the precisely studied and evaluated data of the global market players and their scope in the market using a number of analytical tools. The analytical tools such as investment return analysis, SWOT analysis, and feasibility study are used to analyze the key global market players growth in the Serum-Free Media industry.

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering the business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering the business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPhone no: +1-408-844-4624 / +91- 7030626939Email: sales@alexareports.comSite: https://www.alexareports.com

Read the original post:
Major Players of Serum-Free Media Market By Type: protein expression media, stem cell media, hybridoma media, primary cell media, insect cell media -...

Cancer Stem Cell Market Insights on Upcoming Trends 2025 – Spaceflight News

Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through generation of new tumor. Thus, with advancement in technology especially in cancer stem cells research area, therapies specific to targeting cancer stem cells are expected to improve quality of life and survival cases of cancer patients with metastatic diseases.North America was the leading revenue contributor of the cancer stem cells market in 2016 due to presence of a substantial number of organizations engaged in conducting R&D activities related to stem cell therapy. There are several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, which offer stem cell transplant therapies.Asia Pacific is expected to be a promising region in the arena owing to presence of several organizations in the region that focus on R&D of stem cells. Moreover, funding agencies are providing grants to research communities to accelerate their scientific research on cancer stem cells in Asian countries.In 2018, the global Cancer Stem Cell market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Cancer Stem Cell status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Stem Cell development in United States, Europe and China.

The key players covered in this studyThermo Fisher Scientific, Inc.AbbVie, Inc.Merck KGaABionomicsLonzaStemline Therapeutics, Inc.Miltenyi BiotecPromoCell GmbHMacroGenics, Inc.OncoMed Pharmaceuticals, Inc.

Request Sample Report Athttps://www.researchmoz.us/enquiry.php?type=S&repid=2057238&source=atmIrvine ScientificSTEMCELL Technologies Inc.Sino Biological Inc.BIOTIME, Inc.

Market segment by Type, the product can be split intoCell CulturingCell SeparationCell AnalysisMolecular AnalysisOthers

Market segment by Application, split intoStem Cell Based Cancer TherapyTargeted CSCs

Market segment by Regions/Countries, this report coversUnited States

Make An EnquiryAbout This Report @https://www.researchmoz.us/enquiry.php?type=E&repid=2057238&source=atmEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Cancer Stem Cell status, future forecast, growth opportunity, key market and key players.To present the Cancer Stem Cell development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Cancer Stem Cell are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @https://www.researchmoz.com/checkout?rep_id=2057238&licType=S&source=atm

Post Views: 51

Follow this link:
Cancer Stem Cell Market Insights on Upcoming Trends 2025 - Spaceflight News

X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj, Ph.D., as Senior Vice President, Research and Development. Dr. Skerlj has twenty-five years of experience leading the discovery and development of small molecule drugs to treat rare diseases, cancer, infection and neurodegenerative diseases. In addition, he was one of the original founders of X4 Pharmaceuticals.

Renatos deep scientific expertise in the research and development of innovative, genetically-targeted treatments, combined with his foundational knowledge of X4 and our novel CXCR4 platform, will be invaluable as we advance our pre-clinical product candidates and further expand our rare disease pipeline, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. We are thrilled to have Renato join our senior leadership team given his instrumental role in the founding of X4.

I am very pleased to become a part of X4s dedicated team of experienced and thoughtful leaders, especially during this exciting period of X4s R&D expansion and corporate growth. I look forward to leading our Vienna-based research team and applying my decades of strategic scientific experience to advance and deliver novel therapeutic options to patients with rare diseases, commented Dr. Skerlj.

Most recently, Dr. Skerlj held drug discovery and development leadership roles at Cambridge-based Lysosomal Therapeutics, Inc. Prior to that, he was interim Head of Small Molecule Discovery at Genzyme, and was part of the executive team at AnorMED, a publicly-traded company that was acquired by Genzyme in 2006. Dr. Skerlj is an inventor of both plerixafor, a stem cell mobilizer approved by the U.S. Food and Drug Administration (FDA) in 2008, and ertapenem, an anti-bacterial approved by the FDA in 2001, and has been responsible for delivering multiple drug candidates into early clinical research. He has authored 65 publications and holds 50 patents. Dr. Skerlj received his Ph.D. in Synthetic Organic Chemistry from the University of British Columbia and completed postdoctoral fellowships at the University of Oxford and Ohio State University.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The companys oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenstrms macroglobulinemia (WM) in 2019. X4 was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit http://www.x4pharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding X4s business strategy, including its clinical development plans. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected, and X4 cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, the risk that any one or more of X4s product candidates will not be successfully developed, approved or commercialized, the risk that X4s ongoing or planned clinical trials and studies may be delayed, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving X4s product candidates and the risk that costs required to develop X4s product candidates or to expand its operations will be higher than anticipated. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled Risk Factors in X4s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as updated by X4s Current Report on Form 8-K filed with the SEC on April 11, 2019, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

The rest is here:
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development - Business Wire